Molecular targeted drugs inhibiting vascular endothelial growth factor (VEGF) or mammalian target of rapamycin (mTOR) have been widely used for patients with metastatic or recurrent clear cell renal cell carcinoma (ccRCC) [1, 2]. This evidence concerns the gene MTOR and clear cell renal carcinoma.